BioDiem secures Japanese patent for BDM-I
BioDiem (ASX:BDM) has expanded its IP protection, securing another Japanese patent for antimicrobial compound BDM-I.
The new patent covers BDM-I as a treatment for malaria and the STD trichomoniasis - both protozoic infections.
BioDiem has already secured similar patents in Europe and the US, and also has patents across all three markets covering BDM-I’s treatment of vulvovaginitis infections caused by thrush, gonorrhoea and chlamydia.
“This latest protozoal patent, coupled with our previous vulvovaginitis patent in key markets, means we now have a comprehensive intellectual property set for the treatment of common female genital health complaints,” BioDiem CEO Julie Phillips said.
BioDiem also has BDM-I patents in Canada, China and Singapore. The company has separately licensed hepatitis B and D vaccine technology from the University of Canberra.
The company is evaluating BDM-I against a range of additional targets, including pneumocystosis, fungal infections and tuberculosis, and the parasitic worms that cause schistosomiasis.
BioDiem shares were trading 11.11% higher at $0.03 as of around 2 pm on Thursday.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
